Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success

Analysts said upcoming data on Pfizer’s obesity pill, danuglipron, will be crucial to how competitive the company can be against Eli Lilly and Novo Nordisk.

Previous post Consumer spending fell in October, according to new CNBC/NRF Retail Monitor tracking card transactions
Next post : Tyson Foods’ stock falls after revenue miss, downbeat outlook as protein production seen declining